Debbie Rigby rounds up the latest in research news
Clinical trials have demonstrated the benefits of colchicine in a range of cardiovascular conditions. Colchicine may reduce the risk of CV death, myocardial infarction, ischaemic stroke and ischaemia-driven revascularization by greater than 30%. The use of colchicine at doses of 0.5–1.0 mg daily in CV trials has proved safe, with gastrointestinal intolerance limiting its use in only 10% of patients.
European Heart Journal, ehab221.
A large real-world study explored the temporal pattern of amputations in more than 3 million patients with type 2 diabetes mellitus. The risk of amputation in patients treated with SGLT-2 inhibitors and incretins was not higher compared with other anti-diabetes drugs. Pre-existing peripheral artery disease was the greatest driver of amputation risk, with a four-fold increased risk of lower limb amputations.
European Heart Journal 2021;18:1728-38.
In a large cohort study of over half a million older persons in England, atrial fibrillation and stroke risk was found to increase with increasing frailty. Frailty was associated with a four-fold increased risk of death in patients with severe frailty compared to fit older people. Gastrointestinal bleeding, falls and, among women, stroke was also significantly increased.
Age and Ageing 2021;50(3):772-9.
A systematic review of 9 studies has found that older age, dementia/cognitive impairment and falls/falls risk are independently associated with the non-prescription of anticoagulation. Conversely, previous stroke/transient ischaemic attack and thromboembolism were independently associated with an increased prescription of anticoagulation.
Age and Ageing 2021;50(3):744-57.